Merrill J. Egorin

Merrill J. Egorin's AcademicInfluence.com Rankings

Merrill J. Egorin

Medical

#3251

World Rank

#3713

Historical Rank

Oncology

#228

World Rank

#236

Historical Rank

Pharmacology

#397

World Rank

#450

Historical Rank

medical Degrees

Merrill J. Egorin

Philosophy

#9327

World Rank

#12867

Historical Rank

Logic

#6311

World Rank

#7820

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Merrill J. Egorin's Degrees

Doctorate Medicine University of Pittsburgh
PhD Pharmacology University of Pittsburgh

Why Is Merrill J. Egorin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Merrill J. Egorin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer (2009) (2855)
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. (1995) (544)
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. (2002) (463)
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 (2006) (428)
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. (1992) (372)
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. (1992) (327)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. (2005) (326)
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. (1984) (311)
Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. (2000) (299)
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer (2007) (274)
High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? (1998) (261)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma (2009) (235)
Effect of St John's Wort on imatinib mesylate pharmacokinetics (2004) (230)
Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis (2006) (220)
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. (1985) (201)
Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers (2005) (197)
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies (2007) (185)
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. (2000) (184)
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. (2003) (177)
Imatinib-induced regression of AIDS-related Kaposi's sarcoma. (2005) (166)
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats (2001) (162)
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma (2004) (154)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker (2009) (151)
Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. (1998) (142)
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. (1998) (141)
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. (2003) (136)
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). (2009) (134)
Pharmacokinetics of high‐dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel (2002) (133)
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. (1998) (130)
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer (2003) (130)
Paclitaxel pharmacokinetics and pharmacodynamics. (1995) (130)
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats (1999) (128)
The Safety and Pharmacokinetics of Single-Agent and Combination Therapy with Megestrol Acetate and Dronabinol for the Treatment of HIV Wasting Syndrome (1997) (125)
Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. (2003) (123)
Pharmacodynamics in cancer therapy. (1990) (122)
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. (2008) (120)
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. (2000) (118)
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. (2003) (112)
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. (2003) (112)
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. (2003) (110)
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study (2007) (105)
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice (2009) (105)
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. (2003) (105)
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. (1995) (105)
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer (2006) (103)
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. (1999) (102)
Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. (2006) (102)
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. (1995) (101)
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. (1991) (98)
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia (2009) (98)
Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas (2011) (93)
In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization (2010) (91)
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. (2002) (91)
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. (2000) (90)
Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers (2007) (89)
Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine (2005) (89)
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. (2010) (89)
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma (2009) (86)
Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial (1993) (85)
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. (2010) (84)
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. (1987) (83)
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. (2000) (81)
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). (2006) (79)
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk (2007) (79)
A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer (1999) (76)
Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics (1997) (73)
Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates (2004) (73)
Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. (1989) (71)
A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies (2008) (70)
A limited sampling strategy for cyclophosphamide pharmacokinetics. (1989) (69)
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. (1984) (69)
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) (2008) (68)
Use of adaptive control with feedback to individualize suramin dosing. (1992) (66)
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. (2008) (66)
Cancer pharmacology in the elderly. (1993) (65)
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. (1996) (65)
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer (2009) (64)
Recombinations of subunits of Phaseolus vulgaris isolectins. (1977) (63)
Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function (2007) (63)
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies (2012) (62)
Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer (2004) (62)
Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. (2002) (62)
The pharmacology of carboplatin. (1989) (62)
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. (1986) (62)
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. (1986) (60)
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. (2009) (60)
A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. (2006) (58)
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. (2009) (57)
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. (1995) (57)
A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors (2008) (57)
Suramin, an active drug for prostate cancer: interim observations in a phase I trial. (1993) (57)
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin (2010) (56)
Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. (2008) (56)
Pharmacodynamic model of topotecan-induced time course of neutropenia. (2001) (56)
Effect of the St. John's Wort Constituent Hyperforin on Docetaxel Metabolism by Human Hepatocyte Cultures (2005) (55)
Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2′-Deoxycytidine in Mice (2006) (54)
Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice (2003) (53)
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. (1997) (51)
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. (2013) (50)
Protective action of glycine in cisplatin nephrotoxicity. (1991) (50)
Population pharmacokinetics of zidovudine (1990) (50)
Effect of antacid on imatinib absorption (2009) (49)
Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma (2011) (48)
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. (1994) (48)
Modulation of Gemcitabine (2′,2′-Difluoro-2′-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine (2008) (47)
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. (2008) (44)
Will imatinib compromise reproductive capacity? (2011) (44)
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. (1999) (44)
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). (1989) (43)
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. (1988) (42)
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors (2010) (42)
Effects of pH and temperature on the stability and decomposition of N,N'N"-triethylenethiophosphoramide in urine and buffer. (1984) (42)
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes (2006) (42)
Prospective Evaluation of Body Surface Area as a Determinant of Paclitaxel Pharmacokinetics and Pharmacodynamics in Women with Solid Tumors (2004) (41)
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. (1993) (41)
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. (1993) (41)
Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. (2001) (41)
A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 (2007) (41)
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. (2002) (40)
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. (2011) (40)
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. (1989) (40)
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies (2009) (40)
Plasma pharmacokinetics and tissue distribution of thiotepa in mice. (1984) (39)
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study (2011) (39)
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1 (2001) (39)
Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with Chronic Myeloid Leukemia (2009) (39)
Androgen-Independent Prostate Cancer (2002) (39)
Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. (2009) (38)
Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. (2003) (38)
Enhancement of Cisplatin [cis-Diammine Dichloroplatinum (II)] Cytotoxicity by O6-Benzylguanine Involves Endoplasmic Reticulum Stress (2008) (38)
Inadvertent intrathecal injection of daunorubicin with fatal outcome. (1992) (38)
A Phase I Study of Hyperthermic Isolated Hepatic Perfusion with Oxaliplatin in the Treatment of Unresectable Liver Metastases from Colorectal Cancer (2009) (37)
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer (2010) (37)
Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants. (1998) (37)
Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing. (2004) (37)
Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. (2003) (37)
Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma. (1989) (37)
Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. (1988) (36)
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide (1982) (35)
Therapeutic drug monitoring in CML patients on imatinib. (2007) (35)
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. (2009) (35)
Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. (1994) (35)
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. (2007) (35)
Comparison of Phaseolus vulgaris cultivars on the basis of isolectin differences. (1981) (34)
Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo1 (2007) (34)
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. (2003) (34)
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. (2000) (32)
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors (2007) (31)
Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts). (2007) (31)
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. (2003) (31)
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. (1996) (31)
Alkylation of DNA with aziridine produced during the hydrolysis of N,N',N''-triethylenethiophosphoramide. (1992) (31)
Effects of storage on the binding of carboplatin to plasma proteins (2004) (30)
A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. (2009) (30)
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent (1999) (30)
Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans. (1986) (29)
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma (2015) (29)
DNA adducts of cisplatin and carboplatin in tissues of cancer patients. (1988) (28)
Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia. (1986) (28)
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. (2008) (28)
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia (2015) (27)
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. (1997) (27)
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. (1987) (27)
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies (1996) (27)
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). (2013) (27)
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis (2008) (26)
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA. (1991) (26)
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. (2008) (26)
Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. (1997) (26)
Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity (2005) (26)
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin (2004) (26)
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial (2002) (26)
Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts (2008) (25)
The plasma pharmacokinetics and tissue distribution of dimethyl sulfoxide in mice. (1983) (25)
Modeling toxicity and response in carboplatin-based combination chemotherapy. (1994) (25)
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. (1995) (25)
Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin). (2004) (25)
Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing (2004) (24)
Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage. (1987) (24)
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. (2000) (24)
In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene (1997) (24)
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. (2001) (23)
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts (2013) (23)
Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts) (2008) (23)
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. (1994) (23)
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies. (2000) (22)
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas (2008) (22)
Daunorubicin and adriamycin metabolism in the golden Syrian hamster (1973) (22)
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies (2012) (22)
Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates (2001) (21)
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors (2004) (21)
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer (2001) (21)
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing (2006) (21)
Overview of recent topics in clinical pharmacology of anticancer agents (2009) (20)
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice (2007) (20)
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. (1998) (20)
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy (2012) (19)
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane. (1996) (19)
Gas-liquid chromatographic analysis of N,N',N''-triethylene thiophosphoramide and N,N',N''-triethylene phosphoramide in biological samples. (1985) (19)
The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: A Historical Perspective (2006) (19)
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. (2007) (18)
Cellular pharmacology of N,N',N''-triethylene thiophosphoramide. (1988) (18)
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer (2012) (18)
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery (2009) (18)
Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii (1996) (18)
A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941 (1996) (18)
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer (2005) (18)
Effect of St. John's Wort on imatinib mesylate pharmacokinetics (2004) (18)
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. (2010) (17)
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103) (2014) (17)
Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells. (1990) (17)
Multicenter Evaluation of a Novel Nanoparticle Immunoassay for 5-Fluorouracil on the Olympus AU400 Analyzer (2009) (17)
Glycine reduces early renal parenchymal uptake of cisplatin. (1993) (17)
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: Report of a Veterans Affairs Cooperative Study (1996) (17)
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. (2002) (16)
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients (2011) (16)
Cellular transport and accumulation of thiotepa in murine, human, and avian cells. (1989) (16)
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies (2011) (16)
Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia (2004) (16)
Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG) (2008) (16)
Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284). (2007) (16)
A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas. (2010) (16)
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building (2012) (15)
Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors (2005) (15)
Comparative molecular field analysis-based predictive model of structure-function relationships of polyamine transport inhibitors in L1210 cells. (1997) (15)
In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. (2004) (15)
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma (2004) (15)
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies (2005) (15)
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. (2004) (15)
Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors (2004) (15)
Stability problems with taxol in mouse plasma during analysis by liquid chromatography. (1993) (15)
Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide. (2010) (15)
Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection. (2006) (14)
Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986). (1985) (14)
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors (2004) (14)
Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma. (2000) (14)
Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. (1997) (14)
Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib (2012) (14)
Cellular pharmacology of N1- and N8-aziridinyl analogues of spermidine. (1994) (13)
Characterization of nonexchangeable radioactivity in L1210 cells incubated with [14C]thiotepa: labeling of phosphatidylethanolamine. (1990) (13)
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer (2001) (13)
Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors (2007) (13)
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine (2005) (13)
Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. (1995) (13)
Utility of individualized carboplatin dosing alone and in combination regimens. (1992) (13)
Approaches to optimal dosing of hexamethylene bisacetamide (2004) (13)
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. (1991) (13)
Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM) (2007) (12)
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies (2005) (12)
Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. (2010) (12)
Interstitial continuous infusion therapy in a malignant glioma model in rats (2009) (12)
Results from Phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. (2004) (12)
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers (2006) (12)
Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites. (1987) (12)
Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide. (1988) (12)
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice (2011) (12)
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors (2006) (12)
Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922). (2006) (12)
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine (2009) (11)
Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) (2006) (11)
In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. (2010) (11)
Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer (2008) (11)
A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. (2006) (11)
Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies (2007) (11)
Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. (1986) (11)
A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. (2009) (10)
Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts (2005) (10)
Inhibitory effects of phytohemagglutinin isolectins L4 and E4 on L1210 cells. (1978) (10)
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. (2009) (10)
Therapeutic Drug Monitoring and Dose Optimisation in Oncology (1992) (10)
The disposition of the new anthracycline antibiotic, menogarol, in mice. (1984) (10)
The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies. (1984) (9)
5-fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study (2004) (9)
Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. (2007) (9)
An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. (2006) (9)
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. (1990) (9)
A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice (2006) (9)
Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide. (1987) (8)
A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide (2004) (8)
Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate (2002) (8)
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. (2005) (8)
Mass Balance Studies (2010) (8)
Further refinement of carboplatin dosing. (1995) (8)
Phase I study of docetaxel and topotecan in patients with solid tumors (2000) (8)
Radioimmunoassay and immunochemistry of Phaseolus vulgaris phytohemagglutinin: verification of isolectin subunit structures. (1982) (8)
The experience with suramin in advanced prostate cancer (1995) (8)
PERINATAL/NEONATAL CASE PRESENTATION Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk (2007) (7)
Induction of human leukemia cell differentiation by regiospecifically acetylated spermidines. (1991) (7)
Phaseolus vulgaris isolectin binding to human erythrocytes. (1979) (7)
Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics (2004) (7)
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma. (2004) (7)
Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity. (2009) (7)
Olive , Cancer of Chemotherapy in a Mouse Model of Pancreatic Inhibition of Hedgehog Signaling Enhances Delivery (2009) (7)
Clinical and Pharmacokinetic Studies on the New Platinum Complex Zeniplatin (CL286,558) (1991) (6)
Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. (2009) (6)
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. (2008) (6)
Phase I and Pharmacokinetic Study ofVorinostat , AHistone Deacetylase Inhibitor , in Combinationwith Carboplatin and Paclitaxel forAdvanced Solid Malignancies (2007) (6)
Phytohemagglutinin isolectin stimulation of glucose utilization by lymphocytes. (1977) (6)
Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysis. (1993) (6)
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer (2004) (6)
A physiologically-based pharmacokinetic (PBPK) and pharmacodynamic (PD) model of docetaxel (Doc) and neutropenia in humans (2007) (5)
Editorial note The anthracycline antibiotics depress left ventricular contractility: a clinical fact or laboratory fancy? (1984) (5)
Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum. (1994) (5)
Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors (2004) (5)
A cyclic imine intermediate in the in vitro metabolic conversion of 1,6-diaminohexane to 6-aminohexanoic acid and caprolactam. (1989) (5)
Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma (2004) (5)
Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers (2013) (5)
Therapeutic drug monitoring in CML patients on imatinib. Authors' reply (2007) (5)
Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice (1996) (5)
Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies. (1989) (5)
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (2019) (5)
A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. (2007) (5)
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide. (2002) (5)
Cellular transport and accumulation of thiotepa. (1990) (5)
The effects of organ dysfunction on drug dosing. (2006) (5)
Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion (2004) (5)
Cytotoxic activity of N1- and N8-aziridinyl analogs of spermidine. (1994) (4)
Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. (2005) (4)
Phase I trials: a strategy of ongoing refinement. (1990) (4)
Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) (2015) (4)
Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells. (1988) (4)
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors. (2003) (4)
Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making. (2006) (4)
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors (2012) (4)
Phase I study of vorinostat plus docetaxel in patients with solid tumor malignancies. (2016) (4)
Phytohemagglutinin isolectin stimulation of human lympocytes cultured in serum free medium. (1978) (4)
Phase I study (twice weekly schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors (2005) (4)
Phase I study of imatinib mesylate and gemcitabine in patients with refractory solid tumor malignancy (2005) (4)
Cisplatin Resistance Inhibition of Glutathione Synthesis Reverses Bcl-2-mediated Updated Version (2003) (4)
Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: Final results. (2007) (4)
Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen) (1985) (4)
Plasma kinetics of aclacinomycin A and its major metabolites in man (2004) (4)
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycyticine (FdCyd) & its metabolites 5-fluoro-2'-deoxyuridine (FdUrd), 5-fluorouracil (FU), 5-fluorouridine (FUrd), & 5-fluorocytosine (FC) in plasma of patients treated with FdCyd. (2006) (4)
Correspondence re: M. J. Egorin et al. Pharmacokinetics and Dosage Reduction of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum in Patients with Impaired Renal Function. Cancer Res., 44: 5432–5438, 1984—Reply (1987) (4)
The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide (2004) (4)
Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations (2005) (3)
Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin. (1998) (3)
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA). (1988) (3)
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide. (1989) (3)
The use of dimethyl sulfoxide to reversibly open the blood-brain barrier to protein. (1983) (3)
Intrapatient consistency of imatinib pharmacokinetics (PK) in patients (pts) with advanced cancers. (2004) (3)
Bcl-2 biomodulation with oblimersen sodium in combination with FOLFOX4 chemotherapy: A phase I study in metastatic colon carcinoma (2005) (3)
Phase I and pharmacokinetic (PK) study of 17-allylamino-17 demethoxygeldanamycin (17-AAG) in combination with weekly paclitaxel for advanced solid malignancies (2007) (3)
Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors (2005) (3)
Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane. (1990) (3)
Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies (2008) (3)
Plasma pharmacokinetics , bioavailability , and tissue distribution in CD 2 F 1 mice of halomon , an antitumor halogenated monoterpene isolated from the red algae (3)
Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs (2015) (3)
COMMENT ON : PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS. AUTHORS' REPLY (1997) (3)
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. (2009) (3)
Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005. (2010) (2)
Adenosine triphosphate-binding cassette proteins and bioavailability: "we can pump you up (or out)". (2000) (2)
Topoisomerase Inhibitors Conference University of Maryland Cancer Center, 27-30 October 1993, Monterey, California, USA (1994) (2)
Analysis of renal function in patients entered onto CTEP-sponsored phase I studies since 1979 (2007) (2)
Drug plasma monitoring in CML and GIST: A case-based discussion. (2009) (2)
Intraperitoneal gemcitabine therapy for advanced adenocarcinoma of the pancreas (2004) (2)
Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors. (2004) (2)
A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. (2009) (2)
A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts (2006) (2)
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. (1996) (2)
Salicylate effects on the response of human lymphocytes to phytohemagglutinin isolectins. (1978) (2)
Preclinical pharmacokinetics and metabolism of benzaldehyde dimethane sulfonate (BEN) (NSC 281612) (2005) (2)
Population Pharmacokinetc/Pharmacodynamic Modeling of Paclitaxel and Carboplatin in Ovarian Cancer (2008) (2)
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-Allylamino-17-demethoxygeldanamycin (17AAG) in children with solid tumors. (2006) (2)
DOES PACLITAXEL PENETRATE INTO BRAIN TUMOR TISSUE ? AUTHOR'S REPLY (1995) (2)
The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in Caucasian and African American patients with solid tumors. (2004) (2)
Bayesian Inference in Physiologically-based Pharmacokinetic Modeling: Application to Aniticancer Drug Development (2004) (2)
A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia (2007) (2)
Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes (2008) (2)
Evaluation of the OncoTCap (Oncology Thinking Cap) simulation in teaching medical students about clinical trials: some successes and some surprises. (2004) (2)
The cellular pharmacology of aziridinylbenzoquinone (asq) (nsc 18296). Abstr. (1982) (2)
Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors. (2004) (1)
Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM). (2010) (1)
Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors (2005) (1)
Phase I and pharmacokinetic trial of oral tributyrin in patients with solid tumors (1997) (1)
Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design (2010) (1)
A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors. (2004) (1)
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (2019) (1)
Pharmacokinetics of the radiation sensitizer gadolinium texaphyrin in a phase IB/II trial for patients with brain metastases receiving whole brain radiation (1998) (1)
Phase I, pharmacokinetic (PK), & pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545) in patients with advanced solid tumors. (2006) (1)
The Clinical Pharmacology of Aclacinomycin-A (1982) (1)
In response to Dr. Ochel (2001) (1)
Phase II AIDS Malignancy Consortium (AMC) trial of imatinib in AIDS-associated Kaposi’s sarcoma (KS) (2010) (1)
Effect of ketoconazole administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib in patients with advanced solid tumors (2007) (1)
Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI #8057). (2010) (1)
Phase I trial of motexafin gadolinium (MGd) and docetaxel (D) chemotherapy in the treatment of advanced solid tumors (2005) (1)
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs (2004) (1)
On the search for new anticancer drugs 14: The plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT) (2004) (1)
Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase 1 trials with chemotherapeutic agents (1997) (1)
Toward Model-Based Chemotherapy Treatment Design (2004) (1)
Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study. (2012) (0)
Effect of proton pump inhibitor co-medication on imatinib disposition: A healthy volunteer study. (2009) (0)
The Metabolism and Disposition of Menogarol (OM; NSC 269148) in Mice and Hamsters (1984) (0)
The effect of food on the oral absorption of 9-nitrocamptothecin (9NC) in patients with relapsed solid tumors. (2004) (0)
444 A phase I/II study of oblimersen sodium in combination with oxaliplatin, 5-FU and leucovorin (FOLFOX4 regimen) in patients with advanced colorectal cancer (2004) (0)
IL-1α Enhancement of Platinum-Mediated Anti-Tumor Activity (1996) (0)
PHARMACOLOGY OF DIAZIQUONE (AZQ) GIVEN BY INTRAVENOUS AND INTRACAROTID INFUSION TO NORMAL AND INTRACRANIAL TUMOR-BEARING PUPPIES (1983) (0)
Case 4. Pulmonary stent migration and ingestion in a lung cancer patient. (2006) (0)
Abstract 5499: Temozolomide (TMZ) cytotoxicity in human melanoma cell lines is enhanced by concomitant treatment with the histone deacetylase (HDAC) inhibitor vorinostat (SAHA) and PARP inhibitor MK-4827 (2011) (0)
Standard (S2S) versus iterative-2 (IT2S) stage population analysis of daunorubicin (D1) and daunorubicinol (D2) pharmacokinetics (1991) (0)
Phase i trial of 5 day continuous infusion hexamethylenebisacetamide nsc 95580 (1986) (0)
mesylate (STI571) for Bcr/Abl-induced leukemia The CNS is a sanctuary for leukemic cells in mice receiving imatinib (2013) (0)
Mechanistically-based pharmacodynamics: molecular response to geldanamycin derivatives in human tumor xenographs (2002) (0)
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions (2004) (0)
Co-modelling of daunorubicin (D1) and daunorubicinol (D2) plasma pharmacokinetics (PKs) and pharmacodynamics (PDs) (1990) (0)
of AyV',/V"-Triethylenethiophosphoramide N,N',N"-Triethylenephosphoramide with Cellular DNA1 (2006) (0)
Microsoft Word-1961616-file00.docx (2010) (0)
Clinical Trials in Special Populations (2011) (0)
Cancer Therapy : Clinical Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma (2009) (0)
Abstract 2532:In vitrocytotoxicity, and pharmacokinetics, tissue distribution, and metabolism of the protein kinase D inhibitors, kb-NB142-70 and kb-NB184-43, in mice bearing human cancer xenografts (2010) (0)
Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC). (2012) (0)
Abstract 5465: Modulation of DMS612 (BEN) pharmacokinetics and metabolism in mice by disulfiram, and aldehyde dehydrogenase inhibitor (2011) (0)
Macromolecular control of l1210 proliferation. Abstr. (1977) (0)
Daunorubicin (DNR) plasma pharmacokinetics (PKs) and pharmacodynamics (PDs) (1990) (0)
Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function (1990) (0)
Abstract 2540: Cytotoxicity, pharmacokinetics and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc (2010) (0)
Abstract 3524: Plasma pharmacokinetics and metabolism of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice (2010) (0)
Effects of pH and Temperature on the Stability and Decomposition of A/,/V'A/"-Triethylenethiophosphoramide in Urine and Buffer1 (2006) (0)
174. Phase I trial of trans-retinoic acid (tra) in solid tumor patients (1992) (0)
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building (2012) (0)
Phase I Clinical and Pharmacokinetic Study of Hexamethylene Bisacetamide (NSC 95580) Administered as a Five-Day Continuous Infusion1 (2006) (0)
Co-modelling of daunorubicin and daunorubicinol pharmacokinetics (1990) (0)
Both DNA and the endoplasmic reticulum are cellular targets for enhancement of cisplatin cytotoxicity by O6-benzylguanine (2007) (0)
Abstract #5443: Pharmacokinetics (PK) of PF-04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor after single and multiple dose administration in patients with refractory solid tumor malignancies (2009) (0)
Memory CD8 T Cell Responses In Vivo Imatinib Mesylate Inhibits Antigen-Specific (2007) (0)
Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors (2016) (0)
Weekly H igh-Dose C alcitriol a nd D ocetaxel i n M etastatic Androgen-Indepen dent P rostate C ancer (2003) (0)
Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions. (2004) (0)
Effect of antacid co-medication on imatinib disposition: A healthy volunteer study (2008) (0)
adult acute nonlymphocytic leukemia Diaziquone given as a continuous infusion is an active agent for relapsed (2011) (0)
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyl transferase inhibitor, zebularine (NSC 309132), in mice, rats, and Rhesus monkeys (2005) (0)
Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM). (2011) (0)
Tolerance of full dose menogarii (NSC hepatic and renal function 269148) in patients with abnormal (1990) (0)
Phase I study of Imatinib Mesylate(Gleevec) and Gemcitabine in patients with refractory solid tumor malignancy (2004) (0)
Fourth NCI - EORTC Symposium on New Drugs in Cancer Therapy Brussels, Belgium December 14–17, 1983 (2004) (0)
Distribution of 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts (2004) (0)
Cancer Therapy : Clinical Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin ' s Lymphomas (2011) (0)
Mass balance and pharmacokinetic (PK) study of zebularine (NSC 309132), a DNA-methyltransferase inhibitor, and three metabolites in mice (2006) (0)
Recombinations of Subunits of Phaseohs uzdgaris Isolectins (2002) (0)
APhase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors (2008) (0)
150. The effect of hexamethylene bisacetamide on the activity of DNA-interactive agents in human colon cancer cell lines (1992) (0)
Analysis of elderly (>= 65 yrs) patients' participation on early phase I clinical trials at two NCI-designated Comprehensive Cancer Centers (2005) (0)
Abstract 5450: Enhanced cytotoxicity of carboplatin and paclitaxel (CP) by vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor, in melanoma cell lines (2010) (0)
Phase I S tudy o f P aclitaxel i n C ombination W ith a Multidrug R esistance M odulator, P SC 8 33 ( Valspodar), i n Refractory M alignancies (2000) (0)
Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC). (2012) (0)
Comparison of Iterative-Two Stage and Bootstrap Sampling Approaches in the Development of a Population Pharmacokinetic Model (1997) (0)
Phase I and pharmacokinetic study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer (0)
Phase I a nd P harmacokinetic T rial o f G emcitabine i n Patients W ith H epatic o r R enal D ysfunction: C ancer a nd Leukemia G roup B 9 565 (2000) (0)
Abstract 4549: Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice (2010) (0)
Phase I and Pharmacokinetic Study of Imatinib Mesylate ( Gleevec ) and Gemcitabine in Patients with Refractory SolidTumors (2007) (0)
Intravesical G emcitabine T herapy f or S uperficial T ransitional Cell C arcinoma o f t he B ladder: A P hase I a nd Pharmacokinetic S tudy (2003) (0)
Plasmacidal activity (PCA) in plasma of acute myelocytic leukemia (AML) patients (pts) receiving daunorubicin (DNR) (1989) (0)
PLASMA AND CEREBROSPINAL-FLUID (CSF) PHARMACOKINETICS OF CYCLOPHOSPHAMIDE (CYC) IN PATIENTS TREATED WITH AND WITHOUT DIMETHYLSULFOXIDE (DMSO) (1981) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Merrill J. Egorin?

Merrill J. Egorin is affiliated with the following schools:

Merrill J. Egorin's Academic­Influence.com Rankings

Merrill J. Egorin's Degrees

Why Is Merrill J. Egorin Influential?

Merrill J. Egorin's Published Works

Published Works

What Schools Are Affiliated With Merrill J. Egorin?

Merrill J. Egorin's AcademicInfluence.com Rankings